A major advance in pancreatic cancer treatment has been cleared by U.S. health officials, marking the first drug of its kind to target a protein driving tumor growth in most cases of the aggressive disease. The therapy represents a shift from traditional approaches, offering a precision-based strategy for patients with limited options. Experts note its potential to improve outcomes in a cancer type with historically poor survival rates. The approval follows years of research into how the protein sustains cancer progression.
U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer, by blocking a protein that fuels tumor growth in the vast majority of cases.
